For millions of adults diligently eating their recommended servings of fruits and vegetables, a troubling gap exists between following conventional dietary advice and actually achieving the flavanol levels shown to protect the heart. This finding challenges a widespread assumption that general healthy-eating guidelines implicitly cover specific bioactive compounds like flavanols — and raises a pressing question about whether those guidelines need a significant upgrade.

Drawing on biomarker data from two large, geographically distinct cohorts — COSMOS in the United States (n = 6,509) and EPIC-Norfolk in the United Kingdom (n = 24,154) — researchers used validated urinary metabolite markers, specifically 5-(3',4'-dihydroxyphenyl)-γ-valerolactone metabolites and structurally related (-)-epicatechin metabolites, to objectively quantify flavanol exposure rather than relying solely on self-reported dietary recall. The threshold of interest was 500 mg of flavanols per day, the intake level demonstrated in the COSMOS randomized trial to produce measurable cardiovascular benefits. Despite higher fruit and vegetable consumption and better overall diet quality — assessed via the Alternative Healthy Eating Index — correlating with greater flavanol intake, fewer than 25% of participants who met existing dietary guidelines reached this 500 mg daily target.

This research sits at a meaningful intersection of nutritional epidemiology and public health policy. The COSMOS trial established flavanols as one of the few plant-derived bioactives with credible, trial-proven cardiovascular benefit at a specific dose — a relatively rare standard of evidence in nutrition science. The current findings suggest that food-source flavanols are highly variable depending on variety, processing, and preparation, meaning even a diet rich in produce cannot guarantee therapeutic exposure. A key limitation is that biomarker-based estimates still carry measurement uncertainty, and the populations studied skew older and health-conscious. Nevertheless, this work strengthens the case for flavanol-specific dietary reference values — an incremental but potentially clinically significant step toward more targeted nutritional guidance for cardiovascular risk reduction.